Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 16/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23913673 | 0.92 | S1PR2 (0.59) | S1PR2KCNH2MAPTL3MBTL1P2RX3 | |
| SCHEMBL23908753 | 0.92 | S1PR2 (0.76) | S1PR2KCNH2KDM4EP2RX3 | |
| SCHEMBL23915607 | 0.90 | S1PR2 (0.56) | S1PR2KCNH2MAPTL3MBTL1KDM4E | |
| SCHEMBL23909110 | 0.86 | S1PR2 (0.83) | S1PR2KCNH2L3MBTL1 | |
| SCHEMBL23909005 | 0.83 | S1PR2 (0.64) | S1PR2KCNH2P2RX3 | |
| SCHEMBL23908774 | 0.83 | S1PR2 (1.00) | S1PR2KCNH2 | |
| SCHEMBL23913183 | 0.81 | S1PR2 (0.65) | S1PR2KCNH2L3MBTL1P2RX3 | |
| SCHEMBL23908891 | 0.81 | S1PR2 (0.60) | S1PR2KCNH2KDM4E | |
| SCHEMBL23908914 | 0.80 | S1PR2 (0.84) | S1PR2KCNH2MAPTL3MBTL1KDM4E | |
| SCHEMBL23909120 | 0.76 | S1PR2 (0.67) | S1PR2KCNH2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | S1PR2 3/4885KCNH2 1865/4885MAPT 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.